In PDAC, elevated TGF-β levels are associated with increased metastasis and poorer prognosis, correlating with larger tumors, lymphatic and distant metastases, as well as advanced tumor stages, ultimately leading to reduced overall survival rates. This evidence concerns the gene TGFB1 and neoplasm.